Background Short-chain fatty acids (SCFAs) produced by the gut microbiota have beneficial anti-inflammatory and gut homeostasis effects and prevent type 1 diabetes (T1D) in mice. Reduced SCFA production indicates a loss of beneficial bacteria, commonly associated with chronic autoimmune and inflammatory diseases, including T1D and type 2 diabetes. Here we addressed whether a metabolite-based dietary supplement has an impact on humans with T1D. We conducted a single-arm pilot-and-feasibility trial with high-amylose maize resistant starch modified with acetate and butyrate (HAMSAB) to assess safety, while monitoring changes in the microbiota in alignment with modulation of the immune system status.

中文翻译：

---

人类 1 型糖尿病中基于代谢物的膳食补充剂与微生物群和免疫调节有关

背景肠道微生物群产生的短链脂肪酸 (SCFA) 具有有益的抗炎和肠道稳态​​作用，并可预防小鼠的 1 型糖尿病 (T1D)。SCFA 产量减少表明有益细菌的减少，通常与慢性自身免疫性疾病和炎症性疾病有关，包括 T1D 和 2 型糖尿病。在这里，我们讨论了基于代谢物的膳食补充剂是否对 T1D 患者有影响。我们使用醋酸和丁酸盐改性的高直链玉米抗性淀粉 (HAMSAB) 进行了一项单臂试点和可行性试验，以评估安全性，同时监测微生物群的变化与免疫系统状态的调节相一致。